Tag Archives: biotech industry

The latest from GlobeImmune

Interview with Timothy C. Rodell, M.D., GlobeImmune CEO & President: Can you describe the top priorities or upcoming milestones for your company? Our phase 2 trial in chronic hepatitis C has completed enrollment and we expect to disclose end of treatment data at the annual meeting of the American Association for the Study of Liver Disease in October.  We also expect to present the final data from this trial, sustained virologic response, early in 2010.  Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Anadys brings together the best of both worlds

Dr. Steve Worland, Ph.D., Anadys Pharmaceuticals, Inc. President, CEO, & Director, discusses the latest developments at the company: Can you describe the top priorities or upcoming milestones for your company? Anadys is focused on the development of ANA598, our non-nucleoside polymerase inhibitor for the treatment of Hepatitis C.  ANA598 is in Phase 2 clinical testing in combination with pegylated interferon-alpha and ribavirin, a current standard of care.  We expect to receive safety and response data Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

U.S. Patent for Resolvin to Enter Human Trials

Resolvyx Pharmaceuticals, Inc. announced the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) for RX-10045, a Resolvin therapeutic set to enter clinical trials. RX-10045 is a topical eye drop that treats chronic dry eye syndrome. Resolvins are naturally-occurring, small molecule lipid mediators that can be used to treat a wide range of diseases, including asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvyx has more Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

What’s New at ImmunoVaccine Technologies

An interview with Dr. Randal Chase, President & CEO of ImmunoVaccine Technologies: Can you describe the top priorities or upcoming milestones for your company? Our first priority is to show the safety of our DepoVax™ vaccine enhancement technology in humans by taking our first product, DPX-0907 therapeutic cancer vaccine into Phase 1 clinical trials. We are anticipating filing an IND for DPX-0907 by the end of 2009 and initiating the trial in Q1 of 2010. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

A Word with Calistoga Pharmaceuticals’ CEO

An interview with Dr. Carol Gallagher, Pharm.D., CEO of Calistoga Pharmaceuticals: Can you describe the top priorities or upcoming milestones for your company? 4Q 2009: Reporting updated efficacy and safety data from the ongoing CAL-101 Phase 1 trial in patients with hematologic malignancies 1H 2010: Initiating a Phase 2 registration program for CAL-101 Initiating a Phase 2 trial evaluating CAL-263, a novel oral delta isoform-selective PI3K inhibitor, in patients with asthma Initiating a Phase 1 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,